Tissue Plasminogen Activator for COVID-19-induced Severe Acute Respiratory Distress Syndrome: A Controlled Clinical Trial.
Naderpour Z, Aliannejad R, Mehrtash V, Mollazadeh R, Hosseini SE, Amini S, Pak N, Motlaq TM, Khodaei B, Jafarzadeh B, Habibi R, Madreseh E, Vasei M, Solaymani-Dodaran M.
Naderpour Z, et al. Among authors: amini s.
Infect Disord Drug Targets. 2025 Jan 28. doi: 10.2174/0118715265331792241227173642. Online ahead of print.
Infect Disord Drug Targets. 2025.
PMID: 39878117
Clinical Trial.